Megan Olsen, MPH, principal at Avalere, provides a comprehensive overlook into the many ways that the COVID-19 pandemic has impacted the cell and gene therapy space.
Megan Olsen, MPH, principal at Avalere, provides a comprehensive overlook into the many ways that the COVID-19 pandemic has impacted the cell and gene therapy space.
Transcript
How has the COVID-19 pandemic impacted the development and utilization of gene and cell therapies?
Olsen: So, the COVID-19 pandemic has had several implications on the health care system more broadly, as well as the cell and gene therapy space, specifically. A few that I would highlight here, certainly, with the pandemic early on, we saw a lot of economic impacts. A lot of people unfortunately lost their jobs and a lot of people who have insurance today get insurance through their jobs. So, as people lost insurance, in many cases, they also unfortunately lost employer-based health insurance. As a result, people may have found themselves uninsured and were not able to secure an additional coverage option or alternative coverage option. In other cases, others might have moved into the Medicaid market if they found themselves eligible for Medicaid in their state, or may have found coverage affordable on the exchanges in their state. So, there are different ways in which patients might have obtained insurance or otherwise remained uninsured after losing the job. And certainly that has implications for cost sharing and benefit design, and for access as well. So, some disruptions there.
And then in the access to care and utilization space, we also saw a lot of declines in care visits in early diagnoses, for instance, with patients not visiting their providers as often, or maybe delaying care and delaying treatment. That could have some long-term implications, particularly as we think about the oncology space if some of those early diagnoses were missed or delayed. So, certainly some utilization effects fall across the system.
Then as we think about the pipeline, there are a lot of cell and gene therapies currently in development. Some of those trials are companies investing in this space felt disruption due to the pandemic as well, whether it was disruptions to ongoing trials and recruitment efforts, or just an inability to invest as much as they might have otherwise given some broader company priorities. I think another aspect to note is the FDA. The FDA is playing a large role in the cell and gene therapy space, but, of course, had to refocus some of its priorities on the pandemic in the near term as well. So, I think it has had many implications, and we'll probably see these continue to play out for some time.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More